The invention provides doughs for a baked- or par-baked yeast-raised product, said doughs comprising added pulse and/or legume protein and at least one added lipase enzyme, as well as methods of producing such doughs, the methods comprising the steps of adding pulse and/or legume protein and at least one lipase enzyme to the doughs, and methods of producing baked or par-baked yeast-raised products comprising pulse and/or legume protein, the methods comprising the steps of providing a dough of the invention and baking or par-baking the yeast-raised dough, and finally also uses of enzyme compositions comprising at least one lipase enzyme for maintaining or improving the volume of a baked or par-baked yeast-raised product made from doughs comprising pulse and/or legume protein.

Described herein are recombinant fermenting organisms having a heterologous polynucleotide encoding a phospholipase. Also described are processes for producing a fermentation product, such as ethanol, from starch or cellulosic-containing material with the recombinant fermenting organisms.

The present disclosure relates to bioactive peptides, compositions, production processes and uses of bioactive peptides based on snake venom as anti-tumoral agents. The disclosed bioactive peptides are synthesized based on the C-terminal of the Crotoxin B and its derivatives. The disclosed peptides demonstrate a lessened toxic effect and an elevated anti-tumoral activity against tumor cells, but specifically against triple-negative breast cancer cells, as compared to current standard care. Therefore, the disclosed bioactive snake venom peptides derived from Crotoxin are for the modulation of cellular proliferation, apoptosis, necrosis and the cycle progression of the tumor cells, especially in the triple negative breast cancer cells, presenting a suitable alternative for the sole or complementary treatment of patients with aggressive solid tumors.

The present disclosure provides compositions and methods for inhibiting T cell senescence and improving T cell immunotherapies. In particular, inhibitors of group IV A phospholipase A.sub.2 are disclosed as useful in modulating the lipid metabolism of cells, in particular effector T cells, such that T reg- and tumor cell-induced cell senescence is abrogated. These methods may be employed with particular utility in adoptive T cell therapies and/or enhanced T cell effector functions in vivo, including those performed in combination with checkpoint blockade therapies.

The present invention relates to a composition for improving obesity, comprising phospholipase A2, which is one of the main components of bee venom, as an active ingredient, and more specifically to: a pharmaceutical composition for preventing or treating obesity, comprising phospholipase A2 as an active ingredient; a functional health food composition for preventing or improving obesity, comprising phospholipase A2 as an active ingredient; a feed composition; a method for preventing or treating obesity, comprising a step of administering a composition comprising phospholipase A2 as an active ingredient to an individual; and a use, for preventing or treating obesity, of a composition comprising phospholipase A2 as an active ingredient. A composition for reducing inflammatory macrophages and for preventing or treating obesity, comprising phospholipase A2, which is a substance of the present invention and a major component of bee venom, as an active ingredient, can be usefully employed as a pharmaceutical composition.

Provided are methods for producing food products comprising recombinant components, and compositions used in and food products produced by such methods.

The present disclosure relates to methods, cells, and compositions for producing a product of interest, e.g., a recombinant protein. In particular, the present disclosure provides improved mammalian cells expressing the product of interest, where the cells (e.g., Chinese Hamster Ovary (CHO) cells) have reduced or eliminated activity, e.g., expression, of certain host cell proteins, e.g., enzymes including, but not limited to, certain lipases, esterases, and/or hydrolases.

The present invention relates to a method of making a dough, said method comprises admixing a dough component, a phospholipase A2 enzyme which acts on N-acyl phosphatidyl ethanolamine at the sn2 position, and an enzyme that acts on a polar lipid at the sn1 position. A food enzyme composition comprising: a phospholipase A2 enzyme which is capable of acting on N-acylphosphatidyl ethanolamine at the sn2 position; and an enzyme that acts on a polar lipid at the sn1 position is also taught.

The present disclosure provides compositions and methods for treating ocular inflammation and ocular fibrosis and/or scarring using a cyclooxygenase 2 serine 516 acetylating agent alone or in combination with a cytosolic phospholipase A2 agonist.

The invention relates to methods of reducing foam during ethanol fermentation by adding a phospholipase A and/or a phospholipase C during fermentation.